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In this paper, a cardiac surgeon and an interventional cardiologist draw lessons from the 
trials of PCI/CABG for the TAVI/SAVR era. Both PCI and CABG are effective treatments, but 
do the trials ask the right questions? They dwell on デｴW けWｷデｴWヴ/ﾗヴげ decision for selected 
patients suitable for both treatments, but provide ﾉｷデデﾉW ｪ┌ｷS;ﾐIW aﾗヴ デｴW ﾏ;ﾃﾗヴｷデ┞ ﾗa けヴW;ﾉ 
┘ﾗヴﾉSげ ヮ;デｷWﾐデゲ with comorbidities precluding CABG, or complex CHD precluding PCI. The 
control group must be meaningful and relevant. The pace of technological and therapeutic 
change causes trials to date rapidly. Procedures often do not reflect everyday practice, such 
as performing multi-vessel PCI, copious stenting and full arterial grafting.  Composite 
endpoints such as MACCE provide statistical significance but little insight into patient-
orientated needs. There is a variety of temporal, safety, symptomatic and prognostic 
endpoints, provoking debate over their relative and absolute magnitude and importance; 
and there are issues of interpretation and inappropriate extrapolation. Trial interpretation, 
crystallised in the Kaplan-Meier curve, focuses on the relative benefit of one treatment over 
another, but deserves careful scrutiny. Subgroup analysis tends to exceed its role in dealing 
with issues such as poor LV function, diabetes, multi-vessel disease and proximal LAD 
stenosis. Meta-analysis is controversial and guidelines date rapidly, lacking robust evidence 
in some domains, yet assuming considerable importance. Measures of frailty, physiological 
ﾏW;ゲ┌ヴWゲ ﾗa HﾉﾗﾗS aﾉﾗ┘が けヴW;ﾉ ┘ﾗヴﾉSげ ;Iデｷ┗ｷデ┞ ﾉW┗Wﾉゲが ;ﾐS ヮヴWSｷIデｷﾗﾐゲ ﾗa benefit rarely feature. 
The multidisciplinary (Heart) Team meeting, now integral to study design, is challenging to 
deliver in practice.  The PCI/CABG trials, and the issues arising from them, provide salutary 





It is unusual to have two excellent alternative treatments for a single condition, such as 
coronary artery bypass surgery (CABG) and percutaneous coronary intervention (PCI) for 
coronary artery disease (CAD), and surgical aortic valve replacement (SAVR) and 
transcatheter aortic valve implantation (TAVI) for aortic stenosis (AS). There is concern that 
a newer technology may exceed its evidence base, being less invasive and more convenient 
than the older one; particularly when the results of the tried and tested technology, in 
selected patients, are excellent.  
 
In the 1970s, the only form of revascularisation for coronary artery disease was CABG, and 
comparison with the medical therapy of the time revealed superior results to medical 
therapy (1). When PCI was introduced in the 1980s there were initially no stents or optimal 
antiplatelet agents, but it provided an instant けhitげ with reasonable safety and durability. The 
convenience of the procedure outweighed the risks, and its growth was accompanied by 
development of stents, drug-eluting stents (DES), improved medical therapy, radial 
approaches and applicability in most syndromes. That made PCI seductive. Developments in 
CABG were less dramatic but tangible, with widespread adoption of the internal mammary 
artery conduit, and some surgeons adopting full arterial revascularisation and off-pump 
surgery. From the 1990s onwards, as both PCI and CABG matured, a number of randomised 
trials emerged comparing these modes of revascularisation (2-10). Two developments limit 
applicability of the early trial findings to current practice; later improvements in PCI 
technology and adjunctive therapy, and an increased focus on emergency patients. This led 
to coronary angiography with follow-on ふけ;S ｴﾗIげぶ PCI; efficient in many patients with one or 
two vessel disease and a straightforward clinical syndrome, but controversial in more 
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complex patients for whom surgery might have been better. Surgical unease is tempered by 
the sheer numbers, and the capability of PCI to treat the critically ill and those with 
morbidities that confer high risk for CABG.   
 
Now, with ageing of the population, and many patients with degenerate AS, we have a tried 
and tested surgical therapy, and a novel, less invasive alternative. The evidence supporting 
TAVI in patients who are inoperable (11) or at high surgical risk (12) is clear; and excellent 
results are demonstrable for SAVR in surgically fit patients at intermediate risk (13), whilst 
we await data in the low risk. In this paper, we examine issues that arose in the PCI/CABG 
trials that might help inform debate in the TAVI/SAVR era, with specific reference to one of 
the most studied trials in revascularisation of recent years に the Synergy between 
percutaneous coronary intervention with Taxus (stent) and cardiac surgery (SYNTAX) study 
(14). 
 
Big decisions with big implications 
The three outcomes for patients with AS are SAVR, TAVI or no intervention, analogous to 
CABGが PCI ﾗヴ ﾏWSｷI;ﾉ デｴWヴ;ヮ┞が W┝IWヮデ デｴ;デ デｴW けﾐﾗ ｷﾐデWヴ┗Wﾐデｷﾗﾐげ ﾗヮデｷﾗﾐ ｷゲ WaaWIデｷ┗Wﾉ┞ ; SW;デｴ 
sentence, whereas medical therapy for CAD may have a favourable outcome. But patients 
W┝ｷゲデ ﾗﾐ ; けｪヴW┞ ゲI;ﾉWげ ﾗa a┌ﾐIデｷﾗﾐ;ﾉｷデ┞が ｷﾉﾉﾐWゲゲ ;ﾐS Iﾗ-morbidity: at one extreme, unfit for any 
intervention; at the other, suitable for any; and, in between, many in whom there is scope 
for further investigation, discussion and balancing of risks and benefits. Nor is there room 
aﾗヴ ; けHﾉ;Iﾆ ;ﾐS ┘ｴｷデWげ ;ヮヮヴﾗ;Iｴ デﾗ therapy. Neither SAVR nor TAVI confer immortality. The 
timecourse of deterioration is related to comorbidities, left ventricular (LV) function and 
age.  The key is quality of life, and elderly patients often prefer quality to longevity. A 
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technically successful procedure is of little value if the remaining lifespan is spent in a 
nursing home. Will the operation ｷﾏヮヴﾗ┗W デｴW ヮ;デｷWﾐデげゲ ゲ┞ﾏヮデﾗﾏゲ, help the LV recover or 
enable the patient to care for a partner? Does the patient need complete revascularisation 
with long recovery or fixing of an obvious culprit with partial revascularisation and early 
discharge? In patients with AS, these issues frequently co-exist. 
 
Are we asking the right questions? 
Clinical trials are designed to address specific questions. The title of a study may promise a 
general conclusion, such as Percutaneous coronary intervention versus coronary artery 
bypass grafting for severe coronary artery disease. This title conceals a specific hypothesis, 
namely that for patients with three vessel or left main disease, for whom the local cardiac 
surgeon and interventional cardiologist determined that equivalent anatomical 
revascularization could be achieved with either treatment, a non-inferiority comparison will 
be performed for the primary endpoint ʹ death, stroke, MI or repeat revascularization during 
the 12 months after randomization. This example is from SYNTAX (14). Further scrutiny 
reveals even more specificity. Inclusion criteria comprised de novo, previously untreated 
ﾉWゲｷﾗﾐゲが дヵヰХ デ;ヴｪWデ ┗WゲゲWﾉ ゲデWﾐﾗゲｷゲが ゲデ;HﾉW ﾗヴ ┌ﾐゲデ;HﾉW ;ﾐｪｷﾐ; ﾗヴ ふｷﾐデWヴWゲデｷﾐｪﾉ┞ぶ ;デ┞ヮｷI;ﾉ 
chest pain. Patients with no symptoms were allowed, provided evidence of myocardial 
ischemia was documented. Exclusion criteria included previous PCI or CABG, acute 
myocardial infarction (MI), or the need for concomitant cardiac surgery.  Definitions of the 
primary endpoint comprised MACCE, with equally specific definitions, notably for the MI 
component. Applying the findings of the trial depends upon an individual patient fitting the 




The randomised controlled trial (RCT): who is included?  
In the Coronary Artery Surgery Study (CASS) in the 1970s, of 16,626 coronary angiograms 
screened, 2099 met the randomisation criteria and 780 patients were randomised; 5% of 
the original total (1). In SYNTAX, ヴンンΑ ヮ;デｷWﾐデゲ ┘WヴW け;ゲゲWゲゲWS aﾗヴ WﾉｷｪｷHｷﾉｷデ┞げが ヴWヮヴWゲWﾐデｷﾐｪ 
patients with MVD and/or LMS disease that the local cardiologists thought might be suitable 
for such a study. Of those, 1800 (41%) were randomised. The main reasons for exclusion 
were inability to offer complete revascularisation due to the complexity of the CHD (usually 
biasing against PCI) in around 80% or the presence of significant comorbidities (usually 
biasing against CABG) (14). Examples of randomisable and non-randomisable coronary 
arteries are shown in Figure 1. Many of the PCI/CABG trials excluded a large proportion of 
patients seen in everyday practice. Applying the results of such trials to all patients is 
therefore inappropriate. 
 
Do we practise medicine in the trials how we normally do? 
The surgical arm of SYNTAX was pragmatic, with an average of 2.8 grafts; and 97% of 
patients received an arterial graft. These are けヴW;ﾉ ┘ﾗヴﾉSげ aｷｪ┌ヴWゲ (15). In contrast, the PCI 
arm employed an average of 4.6 DES [; けヴW;ﾉ ┘ﾗヴﾉSげ ;┗Wヴ;ｪW HWｷﾐｪ ヱくヵ (16)], with an 
astonishing mean 86 mm stent length; and they were first generation DES, with greater 
restenosis and thrombosis rates than contemporary DES. The requirement for equivalent 
revascularisation demanded a けCABG-ﾉｷﾆWげ PCI, so complete revascularisation was achieved 
in 63% in the surgical arm and in 57% in the PCI arm. It is not surprising, therefore, that PCI 
in SYNTAX was far removed from everyday practice, and associated with inferior results 
compared with CABG in terms of the composite endpoint (14). PCI fared better in SYNTAX II, 
a single-arm study which employed second generation DES; but this was with 84% 
7 
 
intravascular imaging and 83% multi-vessel physiological guidance (17), which are usually 
deployed in <10% patients (16).   
 
Is the control arm meaningful and relevant? 
In the early development of CABG, PCI, SAVR and TAVI, the control group was a non-
interventional cohort (1,2,11,18). The early PCI/CABG studies were in low risk patients, 
whereas TAVI was first studied in those rejected for SAVR (11). Subsequent PCI/CABG trials 
compared the two interventions, providing guidance on selection of treatment modality for 
the few patients suitable for either. Recent re-exploration of the control group occurred in 
the Percutaneous Coronary Intervention in Stable Angina (ORBITA) study. The control arm 
employed a sham procedure and intense physician input, both non-standard, which could 
have conferred unappreciated benefits (19).  The recurring problem that けヴW;ﾉ ┘ﾗヴﾉSげ 
patients are suitable for one or other intervention, but not both, raises the possibility of 
testing strategies of allocation to both treatments. In SYNTAX III, for example, 
randomisation is between two Heart Teams, not two treatments, with patients being 
allocated to their treatment, whether PCI or CABG, dependent upon CTFFR vs traditional 
angiographic guidance (20).  At the moment, investigation continues using the traditional 
SAVR vs TAVI type study, in intermediate and low risk groups.   
 
Are the endpoints right? 
The traditional cardiovascular trial endpoint is an aggregate of major adverse cardiovascular 
events, comprising death, myocardial infarction, stroke and unplanned repeat 
revascularisation (MACCE). Whilst death and stroke are undeniably major and adverse, 
repeat revascularisation (mostly due to restenosis after PCI) is usually not. But the key 
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question is whether this combination is meaningful to patients, or a composite formulated 
to facilitate a statistically significant difference. Similarly, the length of follow-up needs to be 
considered. Follow-up of less than five years mitigates against the survival benefit of CABG 
that accrues for multi-vessel disease beyond that, as shown in SYNTAX and other trials, but 
it successfully captures most of the complications of PCI (14). However, vein graft failure 
may occur later, and is not generally captured. This is important because restenosis after 
stenting usually responds to repeat PCI, whereas a patient with failed SVGs presents a more 
challenging problem. PCI may be readily repeated, in contrast to CABG. Longer timepoints 
also tend to accrue diverse events which dilute the ability of the study to discriminate the 
value of one treatment over another. 
 
What does the patient really want?  
Patient orientated clinical outcomes outcomes (POCE) have only recently been 
systematically studied. For most CAD patients, and particularly in those who are robust 
without other life-threatening co-morbidity, key priorities are to be rid of chest pain and the 
fear of impending mortality as well as long-term quality of life and survival. They generally 
wish to avoid a highly invasive procedure and are concerned by the prospect of a disabling 
complication. A CABG, more than PCI, may durably improve several aspects of health, but 
the particular toll taken on a frail individual can be considerable. It is therefore easy to 
frighten a patient with procedural risk, but Sﾗ ┘W W┝ヮﾉ;ｷﾐ デｴW ｷﾏヮﾉｷI;デｷﾗﾐゲ ﾗa けIﾗﾐゲWヴ┗;デｷ┗Wげ 
treatment clearly? And what weight should be quoted to patients in their early sixties of the 
enduring benefits of internal thoracic arteries that have angiographic patencies exceeding 
90% after two decades of follow-up?  A frequent response to attempts at balanced 
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explanation is けYﾗ┌ ;ヴW デｴW W┝ヮWヴデ, Doctor, you decideくげ Most professionals rise to this 
challenge, but there is a risk of biased decision-making and paternalism.  
 
Symptoms, prognosis and priorities 
A patient surviving a procedure often believes that their life has been saved, but the 
psychological impact of any procedure, therapeutic or not (19), cannot be over-estimated. 
After a procedure an individual is either alive or dead, whatever the prior risk profile, whilst 
population percentages are forgotten. For PCI vs CABG, those initial percent differences are 
generally small (14), but may diverge with time, whereas for SAVR vs TAVI they may be 
larger (12). For the elderly and frail with CHD, the evidence base is sparse, and prognosis is 
of less importance than functionality and independence. The risks of both commission and 
omission in the elderly and frail are often high; and co-morbidities are key in selecting 
treatment. So, whilst open heart surgery is effective but hazardous in this group, partial 
revascularisation with PCI to relieve rest pain may be reasonably effective at far less risk. For 
the young, different priorities apply, with an emphasis upon efficacy, durability, complete 
functional recovery and optimal prognosis. Traditional trial outcomes are therefore of 
limited use in the very elderly, but of more pressing importance in the young. 
 
Misunderstanding the Kaplan-Meier curve  
We regard the randomised controlled trial ;ゲ デｴW けｪﾗﾉS ゲデ;ﾐS;ヴSげ Iﾗﾏヮ;ヴｷﾐｪ デ┘ﾗ デｴWヴ;ヮｷWゲが 
and we are comfortable reading the accompanying Kaplan-Meier (K-M) survival curve (21). 
A trial with large numbers of participants and widely divergent curves is ideal. This is seldom 
achieved, although it has been observed in AS, for example in the treatment of inoperable 
patients with TAVI (11). More often, there are small numbers, close curves, composite 
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endpoints and short followup. We must distinguish absolute from relative benefit, and 
statistical significance from clinical importance. The usual way of reading a K-M curve is 
vertically, comparing percent survival at a given timepoint, using a hazard ratio and a 95% 
confidence interval. From the patientsげ perspective, this is artificial; they want to know if 
they will feel better or live longer. Longer timepoints are valuable. In SYNTAX there was a 
negligible difference in mortality at two years, but an advantage for CABG in intermediate 
and high SYNTAX scoring patients at five years (22).  These, and other points to consider 
when analysing a K-M curve, are shown in Figure 2. 
 
Subgroup analysis  
A pre-specified endpoint for a large, well defined group of patients, with a clinically and 
statistically important inter-treatment difference, provides the ideal basis for guiding 
therapy. Heterogeneity of the patient population makes this challenging. It is therefore 
commonplace to employ sub-group analysis; in the PCI/CABG trials these included particular 
age groups, sexes, presentations, patterns of CHD, levels of LV dysfunction and diabetes. 
This risks bias, the disadvantages of retrospective analysis, and lacks statistical power (23). 
In those circumstances, subgroup analysis should be regarded as hypothesis-generating, 
rather than definitive. An example is diabetes in the Bypass Angioplasty Revascularization 
Investigation (BARI) (6). Prospective testing is then required (24). One partial solution is to 
pre-specify subgroups. A good example is the study of patients with left main disease within 





A headline such as けCABG ｷゲ HWデデWヴ デｴ;ﾐ PCI for patients with diabetes and multi-vessel 
diseaseげ seems to simplify decision-making. Initial reading of the CABG/PCI trials over the 
years would tend to suggest this (6), it is reflected in guidelines (25), and many practitioners 
adopt this as default. Following that guideline in all cases, however, may not be appropriate. 
What is the pattern of the CHD? Does it consist of focal or long lesions? Are the vessels large 
in calibre or small and diffusely diseased? Is the LV function impaired or infarcted? Is the 
patient severely obese? Is there evidence of peripheral arteriopathy, neuropathy, 
nephropathy or other co-morbidities? These are common in diabetics, and would have 
excluded such a patient from entry into the trials. Other examples of patient groups falling 
outside the evidence base are the very elderly, ACS after more than ; aW┘ S;┞ゲ ﾗa けゲWデデﾉｷﾐｪげが 
prior CABG, renal failure, co-existent lung or stroke disease, bleeding problems, and frailty. 
These are all common in everyday practice. Almost invariably, discussion of superiority in 
trials neglects these important considerations.  
 
Pitfalls of the meta-analysis 
Meta-analysis seeks to augment the power of individual RCTs by combining them 
retrospectively and re-analysing the outcomes. It is a controversial approach and, to be 
performed correctly, PRISMA (referred reporting items systematic reviews and meta-
analysis) guidelines must be followed (26). Even so, there are pitfalls. The trials to be 
included frequently have differing study dates, inclusion criteria, endpoints, timepoints, and 
definitions. The data may be inhomogeneous, there may be publication bias, subjectivity in 
selecting eligible studies and statistical challenges such as non-linear correlations and 
multifactorial effects. A good example is the initial study of stent thrombosis with DES 
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presented at the European Society of Cardiology in 2007 (27). The analysis was performed 
without accessing patient-level data from the trials being evaluated. 
 
The muﾉデｷSｷゲIｷヮﾉｷﾐ;ヴ┞ デW;ﾏ ふMDTぶ けHW;ヴデ TW;ﾏげ ﾏWWデｷﾐｪ  
The MDT meeting is indispensable to the design of RCTs that involve procedures performed 
by different disciplines, and is now established in clinical practice. Guidelines for the 
conduct of MDT meetings are helpful (28), but challenging to enact, mostly due to finding 
sufficient time.  However MDTs are also a powerful tool to eliminate potentially 
inappropriate treatment strategies. The majority of patients with straightforward CAD can 
be treated with PCI effectively and quickly, whereas an MDT meeting is most helpful for 
patients with complex disease and in whom surgery is a possibility. Its effectiveness, 
however, depends upon attendance mix, delays, special interests, ownership of the 
decision, willingness of participants to speak up, cross-refer and seek second opinions, 
knowledge base, and other subtle factors such as enthusiasm and vulnerability. There is a 
reliance upon imaging, with poor co-registration of images from diverse sources. The 
patient, and measures of frailty, activity levels and physiology, are usually conspicuous by 
their absence.   
 
Guidelines are guidelines 
Guidelines synthesize the available evidence to manage a condition, such as stable angina 
(24) or AS (29), and have to convey a clear message, even if the evidence is diverse. They 
include a range of sources, and themselves conform to stringent guidelines (30). Guidelines 
declare classes of recommendation (I-III) and levels of evidence (A-C). If several large, well 
conducted RCTs are available with a concordant, clear positive outcome for an intervention, 
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a Class 1A recommendation can be given; but this is not always the caseが ;ﾐS けW┝ヮWヴデ 
ﾗヮｷﾐｷﾗﾐげ ｴ;ゲ デﾗ ゲ┌Hゲデｷデ┌デW. Guidelines date quickly, lag behind published trials and, being 
based upon meta-analyses and large RCTs, perpetuate the limitations associated with those.  
 
Conclusion: PCI and CABG, surgeon and cardiologist 
One treatment bypasses stenoses, the other dilates them; one is well established, the other 
more recently introduced; one is invasive, the other minimally so; one is more complete, the 
other less so (with important implications for long-term survival); one is rapidly evolving, the 
other consistent; one is minimally dependent upon comorbidity, the other more so; each 
has a number of weaknesses; and both are effective. See Figure 3 for a summary. Pitting one 
against the other is only part of the picture. One is better for one patient, and the other for 
another. Trials clarify the strengths and weaknesses of each in the cohort of patients 
considered candidates for either. We have considered the issues relevant to scrutinising the 
trials. See Figure 4 for a summary. Iﾐ デｴW けヴW;ﾉ ┘ﾗヴﾉSげ, however, CABG and PCI co-exist, 
enabling us to offer our patients a comprehensive revascularisation service to suit clinical 
and personal requirements, taking into account age, co-morbidity and activity level. We can 
now ｷﾐデWｪヴ;デW CABG ;ﾐS PCI ｷﾐデﾗ ; ゲデヴ;デWｪ┞が デｴｷﾐﾆｷﾐｪ けﾉﾗﾐｪｷデ┌Sｷﾐ;ﾉﾉ┞げ aﾗヴ デｴW ｷﾐSｷ┗ｷS┌;ﾉ, 
ヴ;デｴWヴ デｴ;ﾐ け┗WヴデｷI;ﾉﾉ┞げ for a group. Competition has given way to complementarity. Perhaps 
we can apply the lessons of 3ヰ ┞W;ヴゲ ﾗa CABG け┗Wヴゲ┌ゲげ PCI デﾗ デｴW デヴW;デﾏWﾐデ ﾗa ヮ;デｷWﾐデゲ ┘ｷデｴ 
AS. 
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Two examples of multi-vessel coronary artery disease; one treatable with PCI or CABG (A), 
the other with neither (B). These are images taken from left coronary angiograms of two 
different patients meriting revascularisation because of chest pain inadequately controlled 
by medical therapy. In case (A), there are proximal, relatively discrete stenoses (arrows) and 
large calibre distal vessels; the former being suitable for stenting, and the latter for bypass 
ｪヴ;aデｷﾐｪく Tｴｷゲ ヮ;デｷWﾐデ ┘ﾗ┌ﾉS ｴ;┗W HWWﾐ けヴ;ﾐSﾗﾏｷゲ;HﾉWげ ｷﾐ ゲデ┌SｷWゲ ﾗa CABG ┗ゲ PCIく Iﾐ I;ゲW ふBぶが 
there is diffuse, severe atherosclerosis affecting all coronary vessels, which are reduced to 
minute calibre, and are suitable for CABG or PCI. This patient would not have been 
randomisable.  In both cases, the left anterior descending artery, the most important vessel, 
is marked (LAD). Any comparative data pertaining to the merits of CABG or PCI would 
therefore not apply to such a patient as (B).  
 
Fig. 2 
Some points to consider when critically evaluating trial results presented in the form of 
Kaplan-Meier curves. In this hypothetical example, outcomes are displayed following two 
different interventional treatments for CAD, portrayed in red and black. (A) The Y axis only 
extends to 30% of patients. The remaining 70% had a favourable outcome and are omitted, 
which tends to exaggerate the visual impact of the absolute, rather than the relative, 
benefit. (B) The outcome measure is MACCE. This is a composite endpoint, and it is useful to 
see the results for the components broken down in a separate table. Often in PCI vs CABG 
trials, mortality is not significantly different, or only minimally so, between the treatment 
groups. (C) Individual adverse events appear as steps up in the curves, and appear to be 
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larger at later timepoints. This is because the number of patients who have reached the 
later timepoints is lower than the number at earlier ones, so the percentage effect of a 
single event is relatively greater. (D) This is also reflected in the larger error bars seen at 
later timepoints. (E) The number of patients studied at each major timepoint (in this case 
every 12 months would suffice) should be shown clearly on the chart. (F) It is not clear at 
┘ｴｷIｴ デｷﾏWヮﾗｷﾐデ デｴW けヮげ ┗;ﾉ┌W ;ヮヮﾉｷWゲく Iデ ｷゲ ┌ﾐﾉｷﾆWﾉ┞ デﾗ HW ;デ デｴヴWW ┞W;ヴゲく ふGぶ Gｷ┗Wﾐ ;ﾉﾉ デｴW 
above limitations, the difference between the two groups at three years may not be as 
impressive as it appears. (H) Of importance, and rarely discussed, is the residual adverse 
event rate. Clearly neither treatment is conferring a perfect clinical outcome. There is still 
room for improvement. (I) Follow-up is only 36 months. In the PCI/CABG trials, this may be 
long enough to capture problems after PCI, but not necessarily the survival advantage of 
CABG usually demonstrable by 5 years. 
 
Fig. 3 
Comparison of the attributes of PCI and CABG, including some which are not generally 
;SSヴWゲゲWS ｷﾐ デヴ;Sｷデｷﾗﾐ;ﾉ けｴW;S-to-ｴW;Sげ デヴｷ;ﾉゲが H┌デ ;ヴW ﾗa ヮヴ;IデｷI;ﾉ ｷﾏヮﾗヴデ;ﾐIW デﾗ ヮ;デｷWﾐデゲく   
 
Fig. 4 
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